CORT125134 Study

This is a clinical trial for patients with Cushing syndrome

Cushing syndrome is a rare disorder caused by lengthy exposure to high levels of cortisol, a hormone naturally produced by the body. Cushing syndrome may result from too much cortisol being produced by the body or as a result of taking steroid medications.

This study is testing a new investigational medication for patients who have Cushing syndrome due to the body’s production of too much cortisol.

Study medication

The investigational treatment (CORT125134) is taken once a day, orally (by mouth).

Study details

This is a Phase 2 trial. A Phase 2 trial means that the study drug has been taken before by healthy volunteers under supervision. In this current trial, the study drug is being used for the first time in patients with Cushing syndrome.

There will be 30 participants in this trial.

Eligibility criteria:

  1. Diagnosis of Cushing syndrome caused by the body’s production of too much cortisol (not caused by steroid medication)
  2. Requires medical treatment for Cushing syndrome
  3. Meets at least one of the following criteria:
    • a. Has type 2 diabetes or impaired glucose tolerance (has a high blood sugar level)
    • b. Has high blood pressure

Exclusion criteria:

Not Allowed
  1. Diagnosis of Cushing syndrome caused by steroid medication
  2. Poorly controlled blood pressure
  3. Severe kidney disease

This study takes place in 5 countries: United States, United Kingdom, Netherlands, Italy, and Hungary

Next Page